Telaprevir

Type: Keyphrase
Name: Telaprevir
First reported 7 hours ago - Updated 7 hours ago - 1 reports

Mitsubishi Tanabe receives approval for additional indication of HCV drug

Mitsubishi Tanabe Pharma Corporation has received approval for an additional indication of TELAVIC 250mg tablets, indicated for the treatment of chronic genotype 2 hepatitis C virus infection, or HCV. Telavic, an oral treatment of chronic hepatitis C, ... [Published Individual.com - 7 hours ago]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Mitsubishi Tanabe Pharma gains approval for Telavic in genotype 2 HCV

Japanese pharma company Mitsubishi Tanabe Pharma (TYO: 4508) has received approval for an additional indication of chronic hepatitis C genotype 2 for Telavic (telaprevir) in Japan.The oral treatment inhibits NS3-4A serine protease to suppress the hepatitis ... [Published Pharma Letter - Sep 22 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Use of Protease Inhibitors in HIV/HCV Genotype 1 Coinfection

Leroy V, Serfaty L, Bourlière M, et al. Protease inhibitorbased triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. Liver Int 2012; 32: 1477–92.Serpaggi J, Chaix M-L, Batisse D, et al. Sexually transmitted ... [Published Diabetes Care - Sep 19 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

"Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis

Research articleManuela Rasi , Patrizia Künzler-Heule , Patrick Schmid , David Semela , Philip Bruggmann , Jan Fehr , Susi Saxer and Dunja NiccaBMC Infectious Diseases 2014, 14 :507doi:10.1186/1471-2334-14-507Published: 18 September 2014Abstract (provisional) ... [Published BMC - Sep 18 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

LT recipients with HCV met SVR with telaprevir, PEG-IFN/RBV

NEW YORK — Liver transplant recipients with hepatitis C virus genotype 1 achieved sustained virologic response by 12 weeks of therapy with telaprevir plus pegylated interferon and ribavirin, according to data presented at the AASLD/EASL Special Conference ... [Published Orthopedics Today - Sep 15 2014]
First reported Sep 11 2014 - Updated Sep 12 2014 - 1 reports

Britain Has No Problem Paying for Expensive Hepatitis C Drugs/Different Healthcare Systems

New Models for Healthcare Funding Needed - (08/06/14)from Jules: it is time to discuss a new model for evaluating new life-saving medical treatments. The federal govt spends $22 bill a year on HIV, $4.5 bill in medicare, $5 bill a year in medicaid, in ... [Published National AIDS Treatment Advocacy Project - Sep 11 2014]
First reported Sep 06 2014 - Updated Sep 06 2014 - 1 reports

Efficacy of triple therapy varied among Israeli patients with HCV

WASHINGTON, D.C. — Israeli patients with hepatitis C virus infection genotype 1 showed varied improvements after protease inhibitor-based triple therapy, according to data presented at ICAAC 2014.Researchers at the Soroka Medical Center in southern Israel ... [Published Orthopedics Today - Sep 06 2014]
Entities: Genotype, Protease, fibrosis
First reported Sep 06 2014 - Updated Sep 06 2014 - 1 reports

Hep C sufferers going untreated

HEALTH workers are calling for two new hepatitis C treatments to be added to the Pharmaceutical Benefits Scheme (PBS) as infection rates in the western suburbs increase.Staff from Hepatitis Victoria, St Vincents Hospital's Werribee hepatitis clinic, primary ... [Published Melton Weekly - Sep 06 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

Treat-all strategy more cost effective than noninvasive tests for HCV patients

The most cost-effective strategy to determine treatment for patients with hepatitis C virus infection in the United Kingdom was to treat all patients regardless of fibrosis stage, according to new study data.Researchers conducted a systematic review of ... [Published Orthopedics Today - Sep 04 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 2 reports

Bristol-Myers’s Breakthrough Drug For HCV Gets Approved

Bristol-Myers has won the EC’s approval for its first-in-line HCV drug, Daklinza. This drug is to be administered with Gilead’s drug Sovaldi for better resultsPage 1 of 2Click Ticker to See live coverageBristol-Myers Squibb Co. ( BMY ) announced yesterday ... [Published Bidness Etc - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 28 2014 - 1 reports

Bristol-Myers Squibb hepatitis C drug cleared for use in Europe

US Bristol-Myers Squibb (NYSE:BMY) saidWednesday that its potent, pan-genotypic NS5A replication complexinhibitor (in-vitro), Daklinza (daclatasvir), had been licensed bythe European Commission (EC) to be used along with other drugs totreat genotypes ... [Published MedCity News - Aug 27 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Incivo and metformin

The summary of product characteristics for Incivo (telaprevir; Janssen-Cilag) now states that c lose monitoring of metformin efficacy and  safety is recommended when starting or stopping Incivo in patients receiving metformin. A dose adjustment of metformin  ... [Published Pharmaceutical Journal - Aug 27 2014]

Quotes

Commenting on the draft guidance Professor Carole Longson, Director of the NICE Centre for Health Technology Evaluation, said: "Chronic hepatitis C can have a significant impact on a person's quality of life, particularly if it progresses to the cirrhosis stages. One of the main challenges in treating hepatitis C is ensuring that people take the drugs they are prescribed. However, current treatment regimens, particularly interferon-based therapy, often have to be given over a long period of time and are associated with significant side effects that increase the likelihood that people may discontinue treatment, or not seek it in the first place."
includes new marketmarket research report "Hepatitis C Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020" to its huge collection of research reports
UK NICE Sovaldi Guidance - "We are pleased to be able to provisionally recommend sofosbuvir as a clinically and cost effective treatment for some people with chronic hepatitis C" - (08/18/14)
...for those in the EU who are in dire need of new treatment choices," said Emmanuel Blin, Head of Worldwide Commercialization, Bristol Myers Squibb . "We are proud to have discovered, developed and now brought to market this first-in-class NS5A replication complex inhibitor. We look forward to our continued work with EU health authorities to ensure Daklinza-based regimens are available to patients as quickly as possible."

More Content

All (61) | News (47) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
NICE consults on draft guidance on the drug sim... [Published National AIDS Treatment Advocacy Project - 1 hour ago]
Hepatitis C Therapeutics Market - Global Indust... [Published SBWire - 3 hours ago]
Mitsubishi Tanabe receives approval for additio... [Published Individual.com - 7 hours ago]
Treatments for Hepatitis C Are Too Expensive fo... [Published SBWire - 8 hours ago]
Sovaldi: Discontinuation, trends, and rationing [Published The Incidental Economist (Posts) - 11 hours ago]
Mitsubishi Tanabe Pharma gains approval for Tel... [Published Pharma Letter - Sep 22 2014]
Use of Protease Inhibitors in HIV/HCV Genotype ... [Published Diabetes Care - Sep 19 2014]
"Fighting an uphill battle": experience with th... [Published BMC - Sep 18 2014]
Johnson & Johnson: Slow And Steady Core Holding... [Published Seeking Alpha - Sep 17 2014]
LT recipients with HCV met SVR with telaprevir,... [Published Orthopedics Today - Sep 15 2014]
Ribavirin added to daclatasvir, sofosbuvir incr... [Published Orthopedics Today - Sep 15 2014]
Added benefit for certain patients found by IQW... [Published Pharma Letter - Sep 15 2014]
FirstWord Lists: The curious case of disappeari... [Published FirstWord Pharma - Sep 15 2014]
Medicaid HCV Treatment Restrictions Denying Car... [Published National AIDS Treatment Advocacy Project - Sep 11 2014]
Britain Has No Problem Paying for Expensive Hep... [Published National AIDS Treatment Advocacy Project - Sep 11 2014]
Bristol Myers Squibb : Updates on European Comm... [Published 4 Traders - Sep 10 2014]
Simeprevir in hepatitis C: Added benefit for ce... [Published EurekAlert! - Sep 08 2014]
ICAAC 2014: AbbVie 3D Regimen Works Well for Pe... [Published HIV and Hepatitis.com - Sep 08 2014]
Liver Cancer A Cancer You Can Catch [Published Girl.com.au - Sep 08 2014]
Efficacy of triple therapy varied among Israeli... [Published Orthopedics Today - Sep 06 2014]
Hep C sufferers going untreated [Published Melton Weekly - Sep 06 2014]
Treat-all strategy more cost effective than non... [Published Orthopedics Today - Sep 04 2014]
American Patients Forced to Subsidize Others Du... [Published Digital Journal - Sep 04 2014]
Is Treating Hepatitis C Cost-Effective? [Published The AIDS Reader - Sep 02 2014]
Bristol-Myers Squibb Reports European Commissio... [Published Individual.com - Sep 02 2014]
New Summary: Clinical Pharmacogenetics Implemen... [Published National Guideline Clearinghouse - Sep 01 2014]
Hepatitis C [Published Newmarket Journal - Aug 30 2014]
Thousands get a cure as Hep C drugs makes PBS list [Published Bega District News - Aug 29 2014]
HCV Is Even More Dangerous During Menopause; CB... [Published SBWire - Aug 28 2014]
Bristol-Myers’s Breakthrough Drug For HCV Gets ... [Published Bidness Etc - Aug 28 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Sovaldi: Discontinuation, trends, and rationing [Published The Incidental Economist (Posts) - 11 hours ago]
The following is a guest post by Allan Joseph, a medical student at the Warren Alpert Medical School of Brown University and TIE research assistant. You can follow Allan on Twitter: @allanmjoseph . You can read previous TIE coverage of Sovaldi here ...
The Hepatitis C virus is the main cause of live... [Published PR Newswire: General Business - Jul 25 2014]
PORT OF SPAIN, Trinidad and Tobago, July 25, 2014 /PRNewswire/ -- The Chemistry, Food & Drugs Division of the Trinidad & Tobago Ministry of Health approved the introduction of Telaprevir to the market, an innovative therapy that significantly increases ...
Treating Hepatitis C: Criticisms of sofosbuvir [Published The Incidental Economist (Posts) - Jun 17 2014]
The following is part of a series of guest posts on hepatitis C by Allan Joseph, a medical student at the Warren Alpert Medical School of Brown University and TIE research assistant. You can follow Allan on Twitter:  @allanmjoseph . Links to all posts ...
Treating Hepatitis C: Sofosbuvir [Published The Incidental Economist (Posts) - Jun 16 2014]
The following is part of a series of guest posts on hepatitis C by Allan Joseph, a medical student at the Warren Alpert Medical School of Brown University and TIE research assistant. You can follow Allan on Twitter:  @allanmjoseph . Links to all posts ...
Treating hepatitis C: Treatment options before ... [Published The Incidental Economist (Posts) - Jun 13 2014]
The following is part of a series of guest posts on hepatitis C by Allan Joseph, a medical student at the Warren Alpert Medical School of Brown University and TIE research assistant. You can follow Allan on Twitter:  @allanmjoseph . Links to all posts ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.